Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients - Abstract

OBJECTIVE: To examine the rates of hospitalization in patients with metastatic prostate cancer (mCaP), as well as the effect of hospice utilization on the cost patterns of mCaP.

Over the past decade, dramatic changes in the management of advanced prostate cancer have proceeded alongside changes in end-of-life care. But, the impact of these contemporary advances in management of mCaP and its implications on US health care expenditure remains unknown.

METHODS: Patients hospitalized with mCaP from 1998 to 2010 were extracted from the Nationwide Inpatient Sample (n = 100,220). Temporal trends in incidence and charges were assessed by linear regression. Complex samples logistic regression models were used to identify the predictors of in-hospital mortality, elevated hospital charges beyond the 75th percentile and hospice utilization.

RESULTS: Between 1998 and 2010, admissions for mCaP decreased at a rate of -5.95% per year (P < .001), whereas per-incident charges increased at the rate of 6.1% (P < .001) annually; the national economic burden of care was stable. Over the study period, hospice use increased 488.0% per year (P < .001) but was significantly lower among black (odds ratio [OR], 0.73; P = .01) and Hispanic (OR, 0.65; P = .03) patients. In multivariable analyses, hospice utilization was associated with decreased odds of elevated hospital charges beyond the 75th percentile (OR, 0.84; P = .02).

CONCLUSION: Despite a decline in hospitalizations for mCaP, the economic burden of care has remained stable. Increasing use of hospice services has moderated the effect of rising per-incident hospital charges, highlighting the importance of promoting access to hospice in the right clinical setting. These findings have important policy implications, particularly as advances in treatment are expected to further increase expenditures related to the inpatient management of mCaP.

Written by:
Sammon JD, McKay RR, Kim SP, Sood A, Sukumar S, Hayn MH, Hu JC, Kibel AS, Nguyen PL, Peabody JO, Saad F, Sun M, Varda B, Menon M, Choueiri TK, Trinh QD.   Are you the author?
VUI Center for Outcomes Research, Analytics and Evaluation, Henry Ford Health System, Detroit, MI; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Urology, Yale University, New Haven, CN; Division of Urologic Oncology and Center for Surgery and Public Health, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Urology, University of Minnesota, Minneapolis, MN; Department of Urology, Maine Medical Center, Portland, ME; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Division of Urology, University of Montreal Hospital Center, Montreal, Canada; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.  

Reference: Urology. 2015 Feb;85(2):343-9.
doi: 10.1016/j.urology.2014.09.053

PubMed Abstract
PMID: 25623683

UroToday.com Prostate Cancer Section